Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Preferred Shares (2023 - 2025)

Historic Preferred Shares for Lucid Diagnostics (LUCD) over the last 3 years, with Q3 2025 value amounting to $54.3 million.

  • Lucid Diagnostics' Preferred Shares fell 294.18% to $54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.3 million, marking a year-over-year decrease of 294.18%. This contributed to the annual value of $54.4 million for FY2024, which is 19218.26% up from last year.
  • Lucid Diagnostics' Preferred Shares amounted to $54.3 million in Q3 2025, which was down 294.18% from $54.4 million recorded in Q2 2025.
  • Lucid Diagnostics' 5-year Preferred Shares high stood at $55.9 million for Q2 2024, and its period low was $13.6 million during Q1 2023.
  • For the 3-year period, Lucid Diagnostics' Preferred Shares averaged around $39.4 million, with its median value being $54.3 million (2025).
  • In the last 5 years, Lucid Diagnostics' Preferred Shares soared by 31041.47% in 2024 and then plummeted by 294.18% in 2025.
  • Over the past 3 years, Lucid Diagnostics' Preferred Shares (Quarter) stood at $18.6 million in 2023, then skyrocketed by 192.18% to $54.4 million in 2024, then decreased by 0.27% to $54.3 million in 2025.
  • Its last three reported values are $54.3 million in Q3 2025, $54.4 million for Q2 2025, and $54.4 million during Q1 2025.